MedTrace Logo

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.

NCT01699685 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2016-02-09

Study results available
· View outcomes & findings →

Summary

The study purpose is to evaluate the effect of QAB149

* NVA237 vs. QAB149 on static lung hyperinflation.

Conditions

  • Chronic Obstructive Pulmonary Disease: COPD

Interventions

DRUG

QAB149

Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI

DRUG

Placebo

Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI

DRUG

NVA237

Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI

Sponsors & Collaborators

Principal Investigators

  • Corinne Wild, PhD · Novartis Pharmaceuticals

  • Corinne Wild, PhD · Novartis Pharmaceuticals

  • Martin Brutsche, Prof. Dr. med. · Kantonsspital St. Gallen, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699685 on ClinicalTrials.gov